Read twice and referred to the Committee on Finance.

Original title: “S 1565: A bill to amend the Internal Revenue Code of 1986 to allow expenses for parents to be taken into account as medical expenses, and for other purposes.”

Referred to the Committee on Veterans' Affairs, and in addition to the Committee on Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Original title: “HR 7735: Improving Mental Health Support for Servicemembers and Veterans Act”

Referred to the Committee on Foreign Affairs, and in addition to the Committees on Ways and Means, and Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Original title: “HR 7563: Rare Earth Magnet Market Revitalization Act”

Placed on the Union Calendar, Calendar No. 443.

Original title: “HR 2196: National Emergency Medical Services Memorial Extension Act”

Learn how clinicians and practices have achieved patient hypertension control rates of 80% or more—and how you can too.

Original title: “Hypertension Control Champions”

View CDA Toolkits and applicable CDA resources for each NHSN release.

Original title: “Implementation Toolkits & Resources”

View table of Implementation Guides used for NHSN CDA reporting.

Original title: “Guide to CDA Versions”

The Food and Drug Administration (FDA, the Agency, or we) is issuing a final rule to standardize the format of the National Drug Code (NDC). Under this final rule, all FDA-assigned NDCs will be required to be 12 digits in length with 3 distinct segments and 1 uniform format. The first segment is a 6-digit labeler code, the second segment is a 4-digit product code, and the third segment is a 2-digit package code. Additionally, we are revising the drug product barcode label requirements to permit

Original title: “Revising the National Drug Code Format and Drug Label Barcode Requirements”

The Office of Child Care (OCC), Administration for Children and Families (ACF), U.S. Department of Health and Human Services, is requesting a 3-year extension of the Child Care and Development Fund (CCDF) Consumer Education Website and Reports of Serious Injuries and Death (Office of Management and Budget #: 0970-0473, expiration date: May 31, 2026). There are no changes requested to the reporting requirements. Burden estimates have been adjusted.

Original title: “Proposed Information Collection Activity; Child Care and Development Fund (CCDF) Consumer Education Website and Reports of Serious Injuries and Death”

In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the Center for Scientific Review (CSR) National Institutes of Health will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

Original title: “Proposed Collection; 60-Day Comment Request; Early Career Reviewer Program Online Application and Vetting System-Center for Scientific Review (CSR)”

Around the world, governments are experimenting with new policy models, from expanded treatment programs to innovative reimbursement frameworks, to address one of the most persistent barriers in rare disease care: access to high-cost therapies. Expanding eligibility beyond pediatric patients reflects a growing recognition that sustainable rare disease policies must support individuals across their lifespan. The European Union is advancing reforms to its Orphan Drug and Pediatric Medicines Regulations as part of a broader overhaul of pharmaceutical legislation. The strategy supports provincial coverage of rare disease drugs, expanded screening and diagnostics, and improved coordination of treatment decisions across the country. ... Canada’s strategy represents one of the most significant national investments in rare disease access in recent years. By coordinating federal and provincial efforts, the policy aims to reduce geographic inequities and ensure that patients across the country can benefit from new therapies. Changes to this system could significantly affect how companies prioritize rare disease drug development and how quickly therapies reach patients across Europe. The United Kingdom expanded the Innovative Medicines Fund, a program designed to provide early access to promising therapies while additional clinical evidence is collected. Rare disease therapies are a key focus of the fund. ... Rare disease treatments often reach the market with limited clinical trial data due to small patient populations. Taiwan’s approach illustrates how integrated support systems can address the broader social and economic realities faced by patients and caregivers. In 2025, the World Health Assembly adopted a historic rare disease resolution, calling on countries to integrate rare diseases into national health planning and improve access to diagnosis and treatment. The resolution also calls for the development of a 10-year global action plan focused on equity and access.

Original title: “Global Policy Changes Affecting Rare Disease Access”

Referred to the House Committee on Ways and Means.

Original title: “HR 7727: Sustaining Rural Healthcare Act”

Referred to the House Committee on Energy and Commerce.

Original title: “HRES 1087: Recognizing community water fluoridation as a safe, effective public health intervention to prevent tooth decay and promote oral and physical health.”

Referred to the House Committee on Energy and Commerce.

Original title: “HR 3162: Affordable and Safe Prescription Drug Importation Act of 2025”

Having targeted Hims & Hers last year, the FDA has issued warnings to more telehealth companies over their promotion of GLP-1 drugs used to treat diabetes and obesity. In one case, compounded products were linked with multiple ER visits.

Original title: “FDA Sends 30 Warning Letters To Continue Clampdown on Compounded GLP-1s”

The agency zeroed in on claims that compounded GLP-1 drugs are comparable to approved medicines. Elsewhere, a blood pressure drug topped Wall Street expectations and a Merck deal paid dividends.

Original title: “FDA again targets GLP-1 compounders; Intellia to restart heart disease trial”

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Original title: “HR 6766: To amend titles XVIII and XIX of the Social Security Act to require skilled nursing facilities, nursing facilities, intermediate care facilities for the intellectually disabled, and inpatient rehabilitation facilities to permit essential caregivers access during any period in which regular visitation is restricted.”

Referred to the House Committee on Energy and Commerce.

Original title: “HR 5178: Sickle Cell Disease Comprehensive Care Act”

The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by Ecoflora Cares, c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of jagua (genipin-glycine) blue as a color additive in pet foods at levels consistent with good manufacturing practice.

Original title: “Ecoflora Cares; Filing of Color Additive Petition”

The Food and Drug Administration (FDA or we) is announcing that we have filed a food additive petition, submitted by Kemin Industries, Inc., proposing that we amend our food additive regulations to provide for the safe use of chromium propionate as a source of chromium in food for layer and breeding chickens.

Original title: “Kemin Industries, Inc.; Filing of Food Additive Petition (Animal Use)”